Medical weight loss, made simple.
Doctor-guided GLP-1 treatment, personalized to your goals and shipped discreetly to your door.
14.9%
average loss with brand-name semaglutide at 68 weeks (STEP 1)
20.9%
average loss with brand-name tirzepatide at 72 weeks (SURMOUNT-1)
Weekly
one injection a week, or a daily tablet under the tongue

Medically reviewed by Scott Nass, MD, Medical Director
Could a GLP-1 be right for you?
Doctors usually consider a GLP-1 at a BMI of 30 or more, or 27 or more with a weight-related condition. Check yours in a few seconds.
You may be a candidate. A licensed clinician reviews your health and makes the final call.
Your first six months, step by step.
GLP-1s start low and go up every four weeks, so your body can adjust. This is the typical schedule; your clinician sets yours and can slow it down.
2.5 mg
Month 1 · weekly
5 mg
Month 2 · weekly
7.5 mg
Month 3 · weekly
10 mg
Month 4 · weekly
12.5 mg
Month 5 · weekly
15 mg
Month 6 · weekly
Typical escalation from the FDA label of the brand-name medicine. Compounded medicines are prescribed and adjusted by your clinician.
What you pay. Less a month on longer plans.
Today's prices from our catalog. Shipping is free.
Two proven medicines. Different ways of working.
Semaglutide
Tirzepatide
Works on
Activates the GLP-1 receptor to curb appetite and slow digestion.
Activates both the GLP-1 and GIP receptors, two hormones that regulate appetite.
In the trials
14.9% average weight loss at 68 weeks with brand-name 2.4 mg (STEP 1).
20.9% average weight loss at 72 weeks with brand-name 15 mg (SURMOUNT-1).
How you take it
Once a week under the skin, or one tablet under the tongue each day.
Once a week under the skin, or one tablet under the tongue each day.
From
$99/mo
$150/mo
Both are prescribed and followed by a licensed physician, and you can switch as your needs change. Compounded medications are not FDA-approved for safety, efficacy, or quality. Tirzepatide for weight loss, explained
Nearly 74% of adults in the U.S. have overweight or obesity.
Adjust the scale to see the average one-year loss in the trials.
Your current weight (lbs):
220
In one year the average was (lbs):
33
Uses the roughly 15% mean weight loss over about a year in the brand-name trials (STEP 1, semaglutide 2.4 mg: 14.9% at 68 weeks; SURMOUNT-1, tirzepatide 15 mg: 20.9% at 72 weeks), with diet and exercise. A study average, not a prediction of your result; compounded versions were not studied in these trials. Adult figure: CDC, NHANES 2017–2018.
Make it work for the long run.
- Eat enough proteinClinicians usually ask for protein at every meal to help keep muscle while you lose fat.
- Keep liftingStrength training two or three times a week protects muscle and strength.
- Drink more waterSmaller appetites can mean less fluid. Water helps with nausea and constipation.
- Smaller meals, slowerStop when you feel full. Large, fatty meals make side effects worse.
Every weight loss treatment.
12 treatmentsSemaglutide + Glycine
Medical weight management
From $99 · 4-week supply
6 strengths · 250 mcg – 2.5 mg
Already on a GLP-1?
Side effects.
Contact your provider immediately if you have severe stomach pain that does not go away (possible pancreatitis); a lump or swelling in your neck, hoarseness, or trouble swallowing (possible thyroid tumor); severe vomiting or diarrhea with signs of dehydration; symptoms of low blood sugar; or signs of a serious allergic reaction. Regular check-ins help your physician follow your response to treatment.
Common side effects may include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach pain
- Indigestion
- Injection-site reactions
- Tiredness
- Burping
- Hair loss
- Heartburn
Rare, but serious side effects may include:
- Pancreatitis
- Gallbladder problems, including gallstones
- Kidney problems, usually from dehydration
- Severe stomach and bowel problems
- Low blood sugar, especially with insulin or sulfonylureas
- Serious allergic reactions
- Food or liquid getting into the lungs during anesthesia or deep sedation
- Depression or thoughts of suicide (tell your physician)
- Eye problems in people with type 2 diabetes and retinopathy
- Thyroid C-cell tumors in rodents: not for anyone with a personal or family history of medullary thyroid cancer or MEN 2
Your care team.
Licensed in the U.S.
Five physicians and three nurse practitioners, all licensed in the U.S., review every treatment plan before it goes out.

Scott Nass, MD
Medical Director
MD from Charles R. Drew University and UCLA’s David Geffen School of Medicine. Family Medicine residency at Ventura County Medical Center.

Gene Lee, MD
Physician
MD from Temple University’s Lewis Katz School of Medicine. Family Medicine residency at ChristianaCare. Board-certified family physician in Honolulu.

Frank Suppa, DO
Physician
Doctor of Osteopathic Medicine from the New York College of Osteopathic Medicine. Family physician in New York.

Tommy Bledsoe, MD
Physician
MD from Mercer University School of Medicine. Internal Medicine residency at Dartmouth-Hitchcock Medical Center.

Marie Padin, MD
Physician
MD from Universidad Autónoma de Guadalajara. General practice and primary care in Hatillo, Puerto Rico, affiliated with Professional Hospital Guaynabo.

Craig Walker, CNP
Family Nurse Practitioner
Master’s degree from Clarkson College. Family nurse practitioner with a background in virtual urgent care.

Dina Whiteaker, APRN
Family Nurse Practitioner
Trained at the University of Nebraska Medical Center. Family nurse practitioner since 2011.

Courtney Patterson-Manfredi, APRN
Family Nurse Practitioner
Family nurse practitioner in Kansas since 2014.
Weight Loss Treatment FAQs
What is medical weight loss?
Weight loss treatment prescribed and followed by a physician: here, GLP-1 medicines such as tirzepatide and semaglutide, alongside diet and activity. A U.S.-licensed physician reviews your health, prescribes only if it fits and adjusts the dose with you.
Is compounded tirzepatide the same as Zepbound?
Both contain tirzepatide, but they are different products. Zepbound® is FDA-approved and made by Eli Lilly; compounded tirzepatide is prepared by a licensed U.S. pharmacy under your prescription and is not FDA-approved. We don't offer Zepbound. Zepbound® is a trademark of Eli Lilly and Company, not affiliated with Zepym Health.
Who is eligible for GLP-1 weight loss treatment?
Generally adults with a BMI of 30 or more, or 27 or more with a weight-related condition. A physician reviews your history before anything is prescribed. GLP-1s are not for people with a personal or family history of medullary thyroid cancer or MEN 2, or during pregnancy.
Semaglutide or tirzepatide?
Semaglutide acts on GLP-1; tirzepatide acts on GLP-1 and GIP and produced more weight loss in its trials. Your physician helps you choose based on your goals, your history and how you tolerate the medicine.
Injection or tablet?
Both come as a weekly injection under the skin or as a tablet that dissolves under the tongue once a day. The tablet avoids needles; your physician explains how each one is taken.
If I've taken a GLP-1 before, can I start at the same dose?
Tell your physician which medicine and dose you took and when. They decide the safest starting point for you.
What side effects should I be aware of?
Nausea, diarrhea, vomiting and constipation are the most common, mostly in the first weeks and when the dose goes up. Severe stomach pain needs medical attention right away.
How long until I see results?
Appetite usually quiets within the first weeks. Weight loss builds month by month as the dose steps up; in the trials it continued for more than a year. Results vary.
Is it for both men and women?
Yes. GLP-1 medicines are prescribed to adult men and women who meet the criteria.
How am I billed?
Monthly, every 3 months or every 6 months; longer plans cost less per month. You can pause or cancel anytime.
References
- 1. Once-weekly semaglutide 2.4 mg in adults with overweight or obesity: mean weight change −14.9% vs −2.4% with placebo at 68 weeks. STEP 1. Wilding JPH et al. N Engl J Med, 2021.
- 2. Tirzepatide once weekly for the treatment of obesity: mean weight change −20.9% with 15 mg at 72 weeks. SURMOUNT-1. Jastreboff AM et al. N Engl J Med, 2022.
- 3. 73.6% of U.S. adults aged 20 and over have overweight or obesity. CDC, NCHS. NHANES 2017–2018.
Medical weight loss,
made simple.
Get StartedCompounded medications are not FDA-approved for safety, efficacy, or quality.
